Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

279
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
279
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

264
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
264
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models00:57

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

353
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
353
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

301
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
301
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

257
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
257
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.2K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma.

Future oncology (London, England)·2026
Same author

Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

The AAPS journal·2026
Same author

Bridging preclinical science to clinical design in the development of long-acting injectables: IQ Consortium Industry Perspectives.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

PQRI Workshop: Model-Informed Drug Development (MIDD) Approaches in Pediatric Formulation Development.

The AAPS journal·2026
Same author

Drug Solubilization in Simulated Intestinal Fluids vs Lipophilicity: Does Charge Matter?

Molecular pharmaceutics·2026
Same author

Fraction metabolized by cytochrome P450 enzymes: A comprehensive evaluation of the translatability of an in vitro HepatoPac assay.

Drug metabolism and disposition: the biological fate of chemicals·2026

Related Experiment Video

Updated: Feb 8, 2026

Studying Food Reward and Motivation in Humans
12:09

Studying Food Reward and Motivation in Humans

Published on: March 19, 2014

24.2K

Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.

Christophe Tistaert1, Tycho Heimbach2, Binfeng Xia3

  • 1Pharmaceutical Sciences, Discovery and Manufacturing Sciences, Janssen Research and Development, Beerse, Belgium.

Journal of Pharmaceutical Sciences
|June 16, 2018
PubMed
Summary

Physiologically based pharmacokinetic (PBPK) modeling can predict how food affects drug absorption. This workflow uses existing data to simulate drug behavior, potentially reducing the need for clinical food-effect studies.

Keywords:
Biopharmaceutics Classification System (BCS)absorptionbioavailabilityfood effect(s)food interaction(s)pharmacokineticsphysiologically based pharmacokinetic (PBPK) modeling

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.4K
A Protocol for Computer-Based Protein Structure and Function Prediction
16:41

A Protocol for Computer-Based Protein Structure and Function Prediction

Published on: November 3, 2011

69.8K

Related Experiment Videos

Last Updated: Feb 8, 2026

Studying Food Reward and Motivation in Humans
12:09

Studying Food Reward and Motivation in Humans

Published on: March 19, 2014

24.2K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.4K
A Protocol for Computer-Based Protein Structure and Function Prediction
16:41

A Protocol for Computer-Based Protein Structure and Function Prediction

Published on: November 3, 2011

69.8K

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Computational Biology and Bioinformatics
  • Pharmaceutical Sciences

Background:

  • Food intake significantly impacts oral drug absorption and pharmacokinetic profiles.
  • Physiologically Based Pharmacokinetic (PBPK) modeling offers a powerful in silico tool to simulate drug behavior under various physiological conditions, including fed and fasted states.
  • Advancing PBPK modeling utility is crucial for regulatory decision-making in drug development.

Purpose of the Study:

  • To propose a general, multistep PBPK workflow for predicting food effects on drug absorption.
  • To leverage pre-existing clinical data for immediate-release formulations of Biopharmaceutics Classification System (BCS) I and II compounds.
  • To promote pragmatic PBPK approaches for compounds with well-understood absorption characteristics.

Main Methods:

  • Developed a PBPK workflow integrating solubility and dissolution data for initial model construction.
  • Employed a "middle-out" validation strategy using clinical data from one prandial state.
  • Recommended prospective validation against both fasted and fed state data where feasible.

Main Results:

  • Demonstrated successful prediction of food effects through five case studies using validated PBPK models.
  • Showcased the integration of solubility and dissolution data for robust model development.
  • Confirmed the utility of PBPK models in simulating drug absorption influenced by food.

Conclusions:

  • PBPK models, when combined with limited clinical data, can reliably simulate drug absorption under fed conditions.
  • This approach can potentially replace traditional clinical food-effect studies for new doses, formulations, or API forms.
  • The proposed workflow facilitates the pragmatic application of PBPK for regulatory purposes, particularly for BCS I and II compounds.